파이프라인

학술논문

Cancer Research, online, 2020. Targeting Glycosylated PD-1 Induces Potent Anti-tumor Immunity Linlin Sun, Chia-Wei LI, Ezra M Chung, Riyao Yang, Yong-Soo Kim, Andrew H. Park, Yun-Ju Lai, Yi Yang, Yu-Han Wang, Jielin Liu, Yufan Qiu, Kay-Hooi Khoo, Jun Yao, Jennifer L. Hsu, Jong-Ho Cha, Li-Chuan Chan, Jung-Mao Hsu, Heng-Huan Lee, Stephen S. Yoo and Mien-Chie Hung.

Cancer Cell, 33(2), 2018. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1 Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, Cha JH, Xia W, Chan LC, Kim T, Chang SS, Lee HH, Chou CK, Liu YL, Yeh HC, Perillo EP, Dunn AK, Kuo CW, Khoo KH, Hsu JL, Wu Y, Hsu JM, Yamaguchi H, Huang TH, Sahin AA, Hortobagyi GN, Yoo SS, Hung MC.

Nature communications, 7, 2016. Glycosylation and Stabilization of Programmed Death Ligand-1 Suppresses T-cell Activity Chia-Wei Li, Seung-Oe Lim, Weiya Xia, Heng-Huan Lee, Li-Chuan Chan, Chu-Wei Kuo, Kay-Hooi Khoo, Shih-Shin Chang, Jong-Ho Cha, Taewan Kim, Jennifer L Hsu, Yun Wu, Jung-Mao Hsu, Hirohito Yamaguchi, Qingqing Ding, Yan Wang, Jun Yao, Cheng-Chung Lee, Hsing-Ju Wu, Aysegul A Sahin, James P Allison, Dihua Yu, Gabriel N Hortobagyi, Mien-Chie Hung.

Cancer cell, 30(6), 2016. Deubiquitination and Stabilization of PD-L1 by CSN5 Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC.

Clinical Cancer Research, 22(19), 2016. Implications of the Bystander and Abscopal Effects of Radiation Therapy Verma V, Lin SH.

Journal of Thoracic Oncology, 9(7), 2014. A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Non-Small Cell Lung Cancer Steven H Lin, Jing Zhang, Uma Giri , Clifford Stephan, Mary Sobieski, Ling Zhong, Kathy A Mason, Jessica Molkentine, Howard D Thames, Stephen S Yoo, John V Heymach.

연관논문

Cancer Cell, 36(2), 2019. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, Wei Y, Chou CK, Wang SC, Yan M, Tu CY, Hsia TC, Chiang SF, Chao KSC, Wistuba II, Hsu JL, Hortobagyi GN, Hung MC.

Cancer Research, 78(22), 2018. Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy. Hsu JM, Li CW, Lai YJ, Hung MC.

Molecular Cell, 71(4), 2018. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC.

Nature Communications, 9(1), 2018. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion. Hsu JM, Xia W, Hsu YH, Chan LC, Yu WH, Cha JH, Chen CT, Liao HW, Kuo CW, Khoo KH, Hsu JL, Li CW, Lim SO, Chang SS, Chen YC, Ren GX, Hung MC.

American Journal of Cancer Research, 8(9), 2018. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. Shao B, Li CW, Lim SO, Sun L, Lai YJ, Hou J, Liu C, Chang CW, Qiu Y, Hsu JM, Chan LC, Zha Z, Li H, Hung MC.

Cancer Cell, 33(2), 2018. Glycans Pave the Way for Immunotherapy in Triple-Negative Breast Cancer. Salatino M, Girotti MR, Rabinovich GA.

Front Pharmacology, 9, 2018. Combining Immunotherapy and Radiotherapy for Cancer Treatment: Current Challenges and Future Directions. Wang Y, Deng W, Li N, Neri S, Sharma A, Jiang W, Lin SH.

Lung Cancer, 117, 2018. Spatial interaction of tumor cells and regulatory T cells correlates with survival in non-small cell lung cancer.. Barua S, Fang P, Sharma A, Fujimoto J, Wistuba I, Rao AUK, Lin SH.